US Supreme Court Declines To Hear Biologic Drug Patent Fight 13/12/2016 by Intellectual Property Watch Leave a Comment The US Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval before bringing them to the market.
UAEM Targets Accessible Medicines, R&D Financing, Publicly Funded Research 13/12/2016 by Alexandra Nightingale for Intellectual Property Watch 1 Comment From extracurricular creativity to global campaigns, Universities Allied for Essential Medicines (UAEM) continues in its activities to raise awareness and explore how universities can best direct their research and innovations towards promoting global access to medicines. In the next year, UAEM will extend its national and international campaigns to address the high prices of medicines, continue to gather support for a global agreement on research and development and build on the mapping alternative R&D initiatives.
A Look At The UNAIDS Board Debate On IP And Medicines; Outcome Fell Short For Some 12/12/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment The discussion on intellectual property-related barriers to access to medicines was one of the most contentious points of the 39th meeting of the UNAIDS governing board last week. After hours of negotiations, the board agreed that the organisation will keep working on the issue. But developing countries and civil society would have preferred a stronger mandate, according to representatives.
UNAIDS Board Carries Forward Multi-Agency Work On IP Barriers To Medicines Access 09/12/2016 by Catherine Saez, Intellectual Property Watch 1 Comment A meeting of the Board of the Joint United Nations Programme on HIV/AIDS (UNAIDS) has concluded with a set of decisions (attached) showing that the Board went farther than just noting the UNAIDS secretariat report on intellectual property-related barriers preventing access to medicines. And the Board, after lengthy discussions, also called on UNAIDS to facilitate discussions on the high-profile report of the United Nations Secretary-General’s High-Level Panel for Access to Medicines.
Open Source Software A Core Competency For Effective Tech M&A 09/12/2016 by Guest contributor for Intellectual Property Watch 3 Comments Imagine your company just acquired its competitor for $100 million. Now imagine the company’s most important asset – its proprietary software – is subject to third-party license conditions that require the proprietary software to be distributed free of charge or in source code form. Or, imagine these license conditions are discovered late in the diligence process, and the cost to replace the offending third-party software will costs tens of thousands of dollars and take months to remediate. Both scenarios exemplify the acute, distinct and often overlooked risks inherent to the commercial use of open source software. An effective tech M&A attorney must appreciate these risks and be prepared to take the steps necessary to mitigate or eliminate them.
US High Court Hears Patent Case With Global Trade Implications 08/12/2016 by Dugie Standeford for Intellectual Property Watch Leave a Comment In a first-impression case with implications for international trade, the United States Supreme Court is set to decide whether the US supplier of a single non-infringing article used in an infringing product abroad can be held liable for worldwide damages under US patent law. The case hinges on the meaning of “substantial” and whether US law can extend beyond its borders.
In Search of Evidence: The IP Statistics For Decision Makers Conference (IPSDM) 2016 08/12/2016 by Guest contributor for Intellectual Property Watch Leave a Comment The annual “Intellectual Property Statistics for Decision Makers Conference” took place in Sydney, Australia on 15-16 November. After Vienna last year, the Organisation for Economic Co-operation and Development (OECD) as the key initiator organised the landmark forum this time with the Australian Government through its national intellectual property office, IP Australia. In this environment where the Australian economy could recently mark its 25 years of continuous growth and where the government just launched a new “National Innovation and Science Agenda” in the form of a new tax reform package, we could follow panel discussions and speeches about how empirical evidence can be gained for innovation.
Els Torreele Named Executive Director Of Global MSF Access Campaign 08/12/2016 by William New, Intellectual Property Watch 2 Comments Veteran public health advocate Els Torreele of Belgium has been named the new executive director of the high-profile Médecins Sans Frontières (MSF, Doctors Without Borders) Access Campaign, based in Geneva.
UNAIDS Board Considers Recommendations On Access To Medicines 07/12/2016 by Catherine Saez, Intellectual Property Watch Leave a Comment The Board of the Joint United Nations Programme on HIV/AIDS (UNAIDS) this week is considering a report calling for the 11 cosponsor agencies of the programme to follow the recommendations of the UN Secretary General’s High-Level Panel on Access to Medicines to improve policy coherence, and to produce reports on the use of intellectual property at country and regional levels, including the use of flexibilities.
US High Court Muddies Rule On Design Patent Damages 07/12/2016 by Steven Seidenberg for Intellectual Property Watch 1 Comment The United States Supreme Court yesterday provided a big victory for Samsung – and common sense, according to many experts. The high court ruled that Samsung need not pay $399 million in damages – all the company’s profits from 11 models of smartphones – simply because one or two tiny components of those phones infringed design patents owned by Apple. But Samsung isn’t out of the woods yet. Because despite the importance of today’s Supreme Court decision, the high court left an even more important issue unresolved.